Member Info for CHELSEA7

Well Ruck, I have said October of late and just changed after Interims to Sept/October, probably closer to September, so I guess I fall into Q3 too.

The raise is far away from here, there are many factors like inflection points, potential deals with Avidamab that could affect the price we can get for a raise, let alone how much for. There is Vulpes Plan B , they must have had that since they have become 17.33% holders, new investment by way of a Placing, like i say numerous factors, more than at any time in the past

There is one big cloud over us removed yesterday, that being the IND Approval for SCIB1, and funny enough immediately seized upon to replace it with a Placing. We have had so many debates over the years on this very subject, and it often deviates between a six month window,"" for those deramping"". I am just hoping and expecting we will see something very different now we have Vulpes on board, they certainly bring something to the BOD which I feel is underated.

Lets see what happens in the coming months, a lot more I suggest than in previous years, and yes the more the better.

GN

Vulpes Plan B??

Buys 20k

Sells 190k

So with Fridays Interims and the IND news yesterday, we have risen 3%.

Yes Ruck agree with most of your post, except for the price of any raising?? Historically yes, perhaps it is time to re-write the history??

A few people commented on a lower than expected rise on the IND Approval, I was OK with it, simply because I wouldn"t have liked to see how we reacted SP wise to shelfing our most developed lead candidate!!

Plenty of inflection points to keep us involved this year IMHO, and we still up 40/50% from Vulpes last buy in (5.2) just a short time ago. Hoping to see buyers return as we approach 7p

Absolutely, we would hope that in all conditions rates of survival have improved, and in some reported they are.

There is still a matter of just over half of cancers (I believe, aststs are changeable) where there is still no treatment available. I remember Bermuda crrecting me in whether Keith Flaherty as any involvement still, well he has, and he must believe we can raise the bar, wherever it lies.

Well there is just a little matter of you replying to questions I posed over the weekend re your comments about Vulpes??

They attracted ten recs so seems it is not just me who wanted to hear your reply.

""After a few hours of honest toil "".....................hmmm

Would just like to add to that that since his first involvement he has seen a multitude of combination treatments and results. He certainly doesn"t feel the bar has been raised, out of our reach!!

Buys 20k

Sells 171k

Just 9 trades

Super post Rats.

7.345 Paid after 2 x50k sells around 7.07., and expecting some bigger buys as we approach 7/7.25

https://twitter.com/search?q=%23WorldCancerDay&src=promoted_trend_click

Afternoon, worth a read. Wild good to see you back.

Totally agree with their view too, in a well written article................

Trinity Delta view: ImmunoBody is the most clinically advanced of Scancell’s three technology platforms. ImmunoBody vaccines have an elegant design that targets dendritic cells. They achieve efficient direct and cross-presentation of specific epitopes (peptide sequences from proteins), and a consistently strong anti-tumour immune response. Promising activity was seen in a SCIB1 monotherapy Phase I/II melanoma study, but the real potential, in our view, is in combination with checkpoint inhibitors. The FDA’s green light for the US arm of the Phase II study is a welcome step forward and allows management to re-build momentum.

We maintain our valuation of £82.0m, equivalent to 17.2p a share. There are various likely catalysts over the coming year; including further AvidiMab collaborations, the SCIB1 UK trial being underway, and news flow on the timings of the first SCIB2 and Moditope clinical studies.

M/Cap Today £30.5m

"" US site initiation activities and patient enrolment will commence alongside clinical site expansion in the UK.""

And I somehow reckon that having FDA Approval will only assist in Local Authorities deciding to allow them tp fund the costs of Keytruda.Just MO

At 7.50....................dare I say a buy, and to many more tomorrow.

Volume 2.259m
Buys 1.227m
Sells 1.042m

And those trades and volumes are increasing week on week.

GN

Buys 1.158m

Sells 1.032m

+9.49%

And 52 Trades....................

!!SP Rise.Today 16:35
Short and sweet lIke an Ass's gallop. Didn't exactly encourage many. IMO.""

LOL

Not exactly encouraging trading, indicative spread 14.67%, actual spread 10%

For 50k

Buys 1.108m

Sells 1.032m

+9.49%,

Well one day the IP will reflect the SP and the progress, patients dosed will start that process in the absence of any deal news.

Meanwhilst volumes, trades and trading opportunities are rising/

A 94k sell at 7.15, hence the tick down to 7p on the bid

DG 15.20...................Should see similar rises as we get site news, numbers, enrolling patients, and first patient dosed if protocol is availed, and even updates of trials earlier than usual, presuming trial starts A.S.A.P

7.8..................+9.49%

Hoping for some decent buys at 7.50, as we did in the last two rises at 7p and 8p